The three kinds of clinical drugs, nifedipine citrate and alfatinib maleate, applied by Shiyao group were accepted
-
Last Update: 2020-04-03
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
According to the website of the State Food and Drug Administration (CFDA) on May 26, two kinds of three kinds of drugs applied for clinical application by Shiyao group, i.e tofetibuk citrate and alfetinib maleate, were accepted, becoming the 21st pharmaceutical product accepted by the company this year This year, Sinopharm group stepped up its follow-up in the field of chemical medicine preparation, and the new drugs intensively applied for involve in many treatment fields, including more than 10 indications such as rheumatoid arthritis, cancer, depression, diabetes, osteoporosis, bronchitis, Parkinson's disease, hepatitis B, etc., of which the majority are anti-cancer drugs In terms of product competition, of the 21 chemical pharmaceutical preparations declared by Shiyao group, only 6 varieties have been produced by domestic enterprises, and the remaining 15 varieties have not been produced by domestic enterprises at present, increasing the layout of high-end generic drugs Last year, Sinopharm group achieved an operating revenue of HK $9.949 billion, of which, the revenue of proprietary drugs was HK $5.754 billion, and the revenue of innovative drugs was HK $1.921 billion, an increase of 49% over last year, becoming the company's main source of profit According to the annual report, the company will further deepen the value-added generic drugs and first-class drugs such as tumor drugs on the basis of strategy this year, especially in terms of anti-tumor drugs.
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
